Vaxxinity (VAXX) 8-K Departure of Directors or Certain Officers

EXHIBIT99.1

VaxxinityAppoints Dr.Peter Powchikto

Board ofDirectors

DALLAS,March21,2022 (GLOBENEWSWIRE)-- Vaxxinity,Inc. (Nasdaq:

VAXX),a U.S.companypioneeringthedevelopmentof anew classof

immunotherapeuticvaccinesfor chronicdiseases,todayannouncedthat

PeterPowchik,M.D. isjoiningits Boardof Directorsandwillbe retiringas

Vaxxinity’sExecutiveVicePresident,Research& Development.This

transitionwill beeffectiveMarch31, 2022andwill increasethe sizeof the

Boardto seven.

“Peterisa rockstarof drugdevelopmentwhohas contributedto the

approvalof overhalfa dozennewdrugsthathelppatientsto thisday.We

are fortunatetohavehim joiningour Boardwherewemay continueto

leveragehis considerableexpertisetodevelopvaccinesandtreat chronic

diseases,”saidLouReese,ExecutiveChairmanof Vaxxinity.

“Vaxxinityis continuingtobuilda world-classteamof scientistsanddrug

developmentexpertswith thedriveto changethewaywe treatchronic

diseases,andhelpingtoachieveour goalof makingsafe,effectiveand

affordabletreatmentstodemocratizehealth,”saidDr.PeterPowchik.“We

havea uniqueplatformthathasthe potentialtodisruptthecurrent

treatmentparadigmsin chronicdiseasesandallowus torethinkhow

medicinesare developedanddelivered.By utilizinga vaccineapproach,

Vaxxinitycannot onlyprovidemedicinesthatare moreaffordableand

convenient,but alsoin combinationsand stagesof diseasethatwere

previouslyimpractical.I lookforwardtomynext chapterwith thisdynamic

company.”

Priorto joiningVaxxinityand itspredecessor,UnitedNeuroscience,Dr.

PowchikwasSeniorVicePresident,Headof ClinicalDevelopmentat

RegeneronPharmaceuticalsfrom2006 to2018,wherehe oversawthe

developmentof Regeneron’sfirstsevenapproveddrugsandhelpedtobuild

its developmentand regulatoryinfrastructure.Peterled thedevelopmentof

multipleproductsto licensureincludingEylea®,Kevzara®,Arcalyst®,

Dupixent®andPraluent®againstPCSK9forhypercholesterolemia.Healso

servedvariousrolesin clinicaldevelopmentincludingat ChugaiPharma

USA,Novartisoverseeingthedevelopmentandapprovalof RitalinLA®and

Focalin®and Sepracorwherehe initiatedthedevelopmentofLunesta®.He

is aboard-certifiedpsychiatristtrainedat NYUSchoolof Medicine,Mount

SinaiMedicalCenter(NYC),andColumbiaUniversityCollegeof Physicians

andSurgeons.

“WethankPeterforhisoutstandingcontributiontoVaxxinityandwarmly

welcomehim toour Boardof Directors,”saidMeiMei Hu,ChiefExecutive

Officerof Vaxxinity.“Peterhasbeen instrumentalin definingour pathand

shapingour journeyto createnextgenerationvaccinesto servethe

underservedaroundtheworldanddemocratizehealth.”

AboutVaxxinity

Vaxxinity,Inc.is apurpose-drivenbiotechnologycompanycommittedto

democratizinghealthcareacrossthe globe.Thecompanyispioneeringa

new classof synthetic,peptide-basedimmunotherapeuticvaccinesaimed

at disruptingtheexistingtreatmentparadigmfor chronicdisease,

increasinglydominatedby monoclonalantibodies,whichsufferfrom

prohibitivecostsand cumbersomeadministration.Thecompany’s

proprietarytechnologyplatformhasenabledtheinnovationof novelpipeline

candidatesdesignedtobringtheefficiencyof vaccinesto thetreatmentof

chronicdiseases,includingAlzheimer’s,Parkinson’s,migraine,and

hypercholesterolemia.Thetechnologyisalso implementedas partof a

COVID-19vaccineprogram.Vaxxinityhasoptimizeditspipelinetoachieve

a potentiallyhistoric,globalimpacton humanhealth.

Formore informationaboutVaxxinity,Inc., visitwww.vaxxinity.comand

followus onsocialmedia@vaxxinity.

Forward-lookingStatement

Thispressreleaseincludesforward-lookingstatementswithinthemeaning

of thePrivateSecuritiesLitigationReformActof 1995.Theuseof certain

words,including"believe,""may,"“continue,”“advancing,”and"will"and

similarexpressions,are intendedto identifyforward-lookingstatements.

Theseforward-lookingstatementsinvolvesubstantialrisksand

uncertainties,includingstatementsthatarebasedon thecurrent

expectationsandassumptionsof Vaxxinity’smanagementaboutthe

developmentof anew classof immunotherapeuticvaccinesand the

innovationandefficacyof Vaxxinity’sproductcandidates.Variousimportant

factorscouldcauseactualresultsor eventstodiffermateriallyfrom those

thatmaybe expressedor impliedby ourforward-lookingstatements.

Additionalimportantfactorstobe consideredin connectionwith forward-

lookingstatementsare describedin the"RiskFactors"sectionof the

Company'sQuarterlyReporton Form10-Qfiledwith theSecuritiesand

ExchangeCommissionon December23,2021.Theforward-looking

statementsare madeas ofthisdateandVaxxinitydoesnot undertakeany

obligationtoupdateany forward-lookingstatements,whetheras aresultof

new information,futureeventsor otherwise,exceptas requiredby law.

Investor ContactClaudia

Styslinger

vaxxinity@argotpartners.com

PressContact

PhilipCowdell

media@vaxxinity.com